Search…

First-line approval for the combined use of new and independent Pol inhibitor SIM0508 with Olaparib.

20/08/2025

On August 20, Akeso Pharma Group's innovative anti-tumor drug company Akeso Zaiming announced that its self-developed anti-tumor candidate drug - DNA polymerase small molecule inhibitor SIM0508 has been approved by the National Medical Products Administration to conduct clinical trials in the treatment of advanced solid tumors in combination with Olaparib.

Latest

1 m ago

Full Refar Electric Group Holdings (01750.HK) released its interim results, with a net profit of 723,000 Hong Kong dollars.

3 m ago

Hengmingda (002947.SZ) released its first-half performance, with a net profit attributable to the parent company of 2.34 billion yuan, an increase of 43.01% year-on-year.

3 m ago

Liu Guozhong emphasized the need to continuously carry out anti-disaster and harvest-related work in arranging the deployment of autumn grain production and agricultural disaster prevention and reduction, ensuring the completion of the annual grain production target.

5 m ago

Kingsoft Cloud: Revenue in the first half of the year was 4.319 billion yuan, a year-on-year increase of 17.8%.

5 m ago

Kingsoft Cloud announced that as of June 30, 2025, the company's operating revenue for the six months increased by 17.8% year-on-year to 4.319 billion yuan; gross profit increased by 7.4% year-on-year to 657 million yuan; and the net loss was 773 million yuan.

See all latest